CLOS
BMRN icon

Compagnie Lombard Odier SCmA’s BioMarin Pharmaceuticals BMRN Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,100
Closed -$5K – 645
2017
Q3 		$5K Sell
2,100
-900
-30% -$79.5K ﹤0.01% 660
2017
Q2 		$11K Buy
3,000
+1,200
+67% +$109K ﹤0.01% 648
2017
Q1 		$10K Buy
+1,800
New +$160K ﹤0.01% 671

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Compagnie Lombard Odier SCmA's BMRN Position: Q1 2022 in Review

Compagnie Lombard Odier SCmA sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 112 shares — an estimated $10K sold.

Compagnie Lombard Odier SCmA first reported a position in BMRN in Q4 2013 and held it in 33 quarters. The position peaked at $3.05M in Q2 2016. 561 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

  • Compagnie Lombard Odier SCmA reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 112 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $10K.
  • Compagnie Lombard Odier SCmA first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 33 quarters.
  • Compagnie Lombard Odier SCmA's BioMarin Pharmaceuticals position peaked at $3.05M in Q2 2016.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2022, filed 27 Apr 2022.